ArticlePloS one2013
Dissection of agonistic and blocking effects of CD200 receptor antibodies.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- CD200R1 modulates myelin phagocytosis and spleen response following spinal cord injury.Scientific reports · 2025Article
- CD200R1-CD200 checkpoint inhibits phagocytosis differently from SIRPα-CD47 to suppress tumor growth.Nature communications · 2025Article
- CD200RCellular & molecular immunology · 2024Article
- Reduced cutaneous CD200:CD200R1 signaling in psoriasis enhances neutrophil recruitment to skin.Immunity, inflammation and disease · 2022Article
- CD200R1 Contributes to Successful Functional Reinnervation after a Sciatic Nerve Injury.Cells · 2022Article
- CD200 Limits Monopoiesis and Monocyte Recruitment in Atherosclerosis.Circulation research · 2021Article
- Article
- The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.PloS one · 2019Article
- Second signals rescue B cells from activation-induced mitochondrial dysfunction and death.Nature immunology · 2018Article
- Toll-like receptor 9 antagonizes antibody affinity maturation.Nature immunology · 2018Article
- A Simple, Versatile Antibody-Based Barcoding Method for Flow Cytometry.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.Immunotherapy · 2016Article
- Durable antitumor responses to CD47 blockade require adaptive immune stimulation.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Article
- Herpesvirus orthologues of CD200 bind host CD200R but not related activating receptors.The Journal of general virology · 2016Article
- Signal-regulatory protein α from the NOD mouse binds human CD47 with an exceptionally high affinity-- implications for engraftment of human cells.Immunology · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The CD200 receptor (CD200R) is present mainly on myeloid cells and gives inhibitory signals when engaged by its ligand CD200. The interaction is currently of therapeutic interest in cancer and inflammation. However functional effects are complicated by the fact that CD200R is itself polymorphic and also a member of a paired receptor family with four closely related gene products in mice called CD200RLa etc. We show that a second allele of CD200R (termed CD200R(2)) that differs in 7 amino acids also binds CD200 but did not react with the widely used CD200R antibody OX110. Biochemical and functional analysis showed that the CD200/CD200R interaction was blocked by the OX131, mAb that recognises both CD200R(1) and CD200R(2), but not by OX110 mAb. Both mAb can give agonistic inhibitory signals but functional analysis shows OX131 mAb also has the potential to block inhibition by preventing the ligand-receptor interaction and hence gives opposing effects. Although OX131 mAb cross-reacts with the activating receptor CD200RLe, it is specific for CD200R in C57BL/6 whilst OX110 mAb cross-reacts on CD200RLc. The results show the importance of the repertoire of paired receptors in strains or individuals and mAb used with implications for paired receptor analysis and therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.